EMICIZUMAB FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A: INTERIM ANALYSIS OF HAVEN 7

被引：0

作者：

Pipe, Steven ^{[1
]}

Collins, Peter ^{[1
]}

Dhalluin, Christophe ^{[1
]}

Kenet, Gili ^{[1
]}

Schmitt, Christophe ^{[1
]}

Buri, Muriel ^{[1
]}

Jimenez-Yuste, Victor ^{[1
]}

Peyvandi, Flora ^{[1
]}

Young, Guy ^{[1
]}

Oldenburg, Johannes ^{[1
]}

ElisaMancuso, Maria ^{[1
]}

Kiialainen, Anna ^{[1
]}

Chang, Tiffany ^{[1
]}

Lehle, Michaela ^{[1
]}

Fijnvandraat, Karin ^{[1
]}

机构：

[1] Childrens Hosp Los Angeles, Los Angeles, CA USA

来源：

PEDIATRIC BLOOD & CANCER | 2023年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2011

引用

页码：S7 / S7

页数：1

共 50 条

[41] Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report
Al-Banaa, Kadhim
Alhillan, Alsadiq
Hawa, Fadi
Mahmood, Raai
Zaki, Ahmed
El Abdallah, Mohamad
ELJack, Ammar
Zimmerman, Jonathan
Musa, Faisal
AMERICAN JOURNAL OF CASE REPORTS, 2019, 20 : 1046 - 1048
[42] Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Albattat, Sami
Alabdultaif, Abbas
Albattat, Fatimah
Albattat, Batla
JOURNAL OF MEDICAL CASE REPORTS, 2023, 17 (01)
[43] Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Sami Albattat
Abbas Alabdultaif
Fatimah Albattat
Batla Albattat
Journal of Medical Case Reports, 17
[44] Emicizumab prophylaxis and health-related outcomes in persons with hemophilia a (PwHA) with inhibitors: HAVEN 1 study
Oldenburg, J.
Mahlangu, J. N.
Bujan, W.
Trask, P. C.
von Mackensen, S.
Callaghan, M. U.
Young, G.
Asikanius, E.
Peyvandi, F.
Santagostino, E.
Kruse-Jarres, R.
Negrier, C.
Kessler, C.
Levy, G. G.
Windyga, J.
Shima, M.
HAEMOPHILIA, 2018, 24 : 89 - 90
[45] Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis
Rivas-Pollmar, Maria Isabel
Alvarez-Roman, Maria Teresa
Butta-Coll, Nora V.
Martin Salces, Monica
Garcia-Barcenilla, Sara
Jimenez-Yuste, Victor
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (09) : 2202 - 2204
[46] Severe Bleeding Events in Hemophilia. Patients Receiving Emicizumab Prophylaxis
Zimowski, Karen L.
Batsuli, Glaivy M.
Bryant, Paulette
McDaniel, Jenny
Tickle, Kelly
Meeks, Shannon L.
Sidonio, Robert F., Jr.
BLOOD, 2019, 134
[47] AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors
Matsushita, Tadashi
Suzuki, Nobuaki
Nagae, Chiai
Nagao, Azusa
Ando, Masahiko
Kuwatsuka, Yachiyo
Nosaka, Daisuke
Kyogoku, Yui
Shimura, Tomomi
Nogami, Keiji
BLOOD, 2023, 142
[48] COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES
Li, N.
Bullement, A.
McMordie, S.
Hatswell, A. J.
Wilson, K.
VALUE IN HEALTH, 2019, 22 : S389 - S389
[49] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH MILD OR MODERATE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: RESULTS FROM THE INTERIM ANALYSIS OF THE HAVEN 6 STUDY
Negrier, C.
Mahlangu, J.
Lehle, M.
Chowdary, P.
Catalani, O.
Jimenez-Yuste, V.
Beckermann, B. M.
Schmitt, C.
Hermans, C.
Ventriglia, G.
Windyga, J.
Kiialainen, A.
d'Oiron, R.
Moorehead, P.
Teodoro, V.
Shapiro, A.
Oldenburg, J.
HAEMOPHILIA, 2022, 28 : 20 - 21
[50] Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)
Kruse-Jarres, Rebecca
Callaghan, Michael U.
Croteau, Stacy E.
Jimenez-Yuste, Victor
Khoo, Liane
Liesner, Ri
Matsushita, Tadashi
Recht, Michael
Young, Guy
Chang, Tiffany
Dhalluin, Christophe
Mu, Yunming
Xu, Jin
Devenport, Jenny
Ko, Richard H.
Solari, Paul
Oldenburg, Johannes
BLOOD, 2017, 130

← 1 2 3 4 5 →